- Home
- FATE vs IPHA Comparison
FATE vs IPHA Comparison
Compare FATE & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FATE | IPHA |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 128.4M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | FATE | IPHA |
|---|---|---|
| Price | $1.19 | $1.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $4.10 | ★ $5.75 |
| AVG Volume (30 Days) | ★ 1.3M | 21.6K |
| Earning Date | 05-12-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,646,000.00 | N/A |
| Revenue This Year | N/A | $181.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.86 | $1.18 |
| 52 Week High | $1.94 | $2.63 |
Technical Indicators
Market Signals| Indicator | FATE | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 47.67 | 52.00 |
| Support Level | $1.06 | $1.18 |
| Resistance Level | $1.30 | $1.88 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 53.70 | 84.38 |
Price Performance
Historical ComparisonAbout FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.